eligibility_summary
Eligible: adults 18–75, ECOG 0–1, ≥3‑mo survival, locally advanced/metastatic NSCLC, adequate organ function, negative pregnancy test, not lactating, contraception, informed consent/compliance. Exclude: other cancer <5 y, unresolved >G1 toxicity, major surgery/biopsy/trauma <28 d, unhealed wounds/fractures, CVA/DVT/PE <6 m, substance abuse/serious mental illness, severe/uncontrolled disease, live vaccine <2 w, severe allergies or mAb/Ig/TQB2928 hypersensitivity, investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib, single-arm study in advanced NSCLC testing: 1) TQB2928: a recombinant fully humanized IgG4 monoclonal antibody (immunotherapy) that promotes macrophage-mediated tumor cell phagocytosis, enhancing innate antitumor activity. 2) Almonertinib mesilate: a third-generation, mutant-selective, irreversible EGFR tyrosine kinase inhibitor (small-molecule targeted therapy). Targets/cells: TQB2928 engages tumor-associated macrophages and innate immune phagocytic pathways, almonertinib inhibits EGFR signaling in EGFR-mutant tumor cells. Aim: assess safety/efficacy and determine RP2D.